NAT-LENALIDOMIDE
As listed in the register: NAT-LENALIDOMIDE
25 mg · capsule
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Lenalidomide
- Made by
- Natco Pharma (Canada) Inc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Lenalidomide). It describes the substance, not this exact product.
Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties.
Cellular activities of lenalidomide are mediated through its target cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex.
Following a single oral administration of [ 14 C]-lenalidomide 25 mg to healthy subjects, approximately 90% and 4% of the radioactive dose was eliminated within ten days in urine and feces, respectively.
Administration of a single 25 mg dose of lenalidomide capsules with a high-fat meal in healthy subjects reduces the extent of absorption, with an approximate 20% decrease in AUC and 50% decrease in C max.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-05-27
Safety of the active substance
From the US prescribing label for the same active substance (Lenalidomide). It describes the substance, not this exact product.
WARNING: EMBRYO-FETAL TOXICITY, HEMATOLOGIC TOXICITY, and VENOUS and ARTERIAL THROMBOEMBOLISM Embryo-Fetal Toxicity Do not use lenalidomide capsules during pregnancy.
- Pregnancy ( Boxed Warning, 4.1, 5.1, 8.1 ).
- Demonstrated severe hypersensitivity to lenalidomide ( 4.2, 5.9, 5.15 ). 4.1 Pregnancy Lenalidomide capsules can cause fetal harm when administered to a pregnant female.
- Limb abnormalities were seen in the offspring of monkeys that were dosed with lenalidomide during organogenesis.
- This effect was seen at all doses tested.
Most common adverse reactions (>15%) include thrombocytopenia, neutropenia, diarrhea, pruritus, rash, fatigue, constipation, nausea, nasopharyngitis, arthralgia, pyrexia, back pain, peripheral edema, cough, dizziness, headache, muscle cramp, dyspnea, pharyngitis, and epistaxis ( 6.1 ).
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States19 matching products
European UnionNo exact match for this strength and form
Spain25 matching products
- LENALIDOMIDA ACCORD 25 mg · cápsula dura
- LENALIDOMIDA ACINO 25 mg · cápsula dura
- LENALIDOMIDA AUROVITAS 25 mg · cápsula dura
- LENALIDOMIDA CIPLA 25 mg · cápsula dura
- LENALIDOMIDA COMBIX 25 mg · cápsula dura
- LENALIDOMIDA DR. REDDYS 25 mg · cápsula dura
- LENALIDOMIDA FRESENIUS KABI 25 mg · cápsula dura
- LENALIDOMIDA GLENMARK 25 mg · cápsula dura
Netherlands20 matching products
- Lenalidomide Accord 25 mg harde capsules 25 mg · capsule, hard
- Lenalidomide Alkaloid-INT 25 mg 25 mg · capsule, hard
- Lenalidomide Amarox 25 mg harde capsules 25 mg · capsule, hard
- Lenalidomide Anabiosis 25 mg harde capsules 25 mg · capsule, hard
- Lenalidomide Devatis 25 mg 25 mg · capsule, hard
- Lenalidomide Eugia 25 mg 25 mg · capsule, hard
- Lenalidomide Fresenius Kabi 25 mg 25 mg · capsule, hard
- Lenalidomide Genthon 25 mg 25 mg · capsule, hard
SwitzerlandNo exact match for this strength and form
Details
| Made by | Natco Pharma (Canada) Inc |
|---|---|
| Active substance | Lenalidomide |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 25 mg |
| Form | capsule |
| Classification | L04AX04 · Cancer treatments and immune-system medicines |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02493918 |
| DPD drug code | 98389 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
7 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.